^(89)SrCl_2联合^(99)Tc-MDP对乳腺癌骨转移骨痛治疗疗效  

Therapeutic evaluation of ^(89)SrCl_2 combined with ^(99)Tc-MDP in treating bone pain of patients with breast cancer and osseous metastasis

作　　者：刘恒超[1] 李卫鹏[1] 申勇[1] 胡永全[1] 马芳[2] 

机构地区：[1]蚌埠医学院第一附属医院核医学科,安徽省蚌埠市233004 [2]蚌埠医学院临床检验诊断学教研室

出　　处：《中国肿瘤临床》2015年第5期297-301,共5页Chinese Journal of Clinical Oncology

摘　　要：目的:观察放射性核素氯化锶(89Sr Cl2)联合锝-99-亚甲基二膦酸盐(99Tc-MDP)治疗乳腺癌骨转移的临床效果。方法:将80例乳腺癌骨转移患者随机分为89Sr Cl2治疗组30例、99Tc-MDP治疗组22例、89Sr Cl2与99Tc-MDP联合治疗组28例3组,观察各组骨痛缓解、骨转移病灶好转和生活质量评分提高情况。结果:骨痛缓解总有效率、生活质量评分提高率在联合治疗组为92.9%(26/28)、78.6%(22/28),均明显高于89Sr Cl2治疗组的73.3%(22/30)、53.3%(16/30)和99Tc-MDP治疗组的63.6%(14/22)、45.5%(10/22),差异具有统计学意义(P<0.05)。骨转移病灶好转有效率在联合治疗组为46.4%(13/28),明显优于99Tc-MDP治疗组的18.2%(4/22),差异具有统计学意义(P<0.05);但与89Sr Cl2治疗组的33.3%(10/30)比较差异无统计学意义(P>0.05)。结论:89Sr Cl2联合99Tc-MDP治疗可显著提高乳腺癌骨转移骨痛疗效,且无明显不良反应。Objective： To evaluate the clinical value of radioactive nuclide strontium chloride（89Sr Cl2） combined with99Tc-MDP in treating patients with breast cancer and osseous metastasis. Methods： A total of 80 patients with breast cancer and experiencing bone pain from osseous metastasis were randomly categorized into three groups. 22 patients were treated with99Tc-MDP（99Tc-MDP group）,30 were treated with89 Sr Cl2（89Sr Cl2group）, and 28 were treated with the combination therapy of89 Sr Cl2and99Tc- MDP（combination group）. The analgesic effect, remission of bone metastases, and quality of life of patients in the three groups were observed before and after treatment. Side effect was also monitored. Results： In the combination group, the overall pain relief rate and the increase rate of life quality score were 92.9%（26/28） and 78.6%（22/28）, respectively. The combination group was statistically significantly different from the two single- treatment groups（P0.05）. The effective rate of metastatic lesions was 46.4%（13/28） in the combination group,which was significantly higher than that in the99Tc-MDP group（18.2%, 4/22; P0.05）. The effective rate of metastatic lesions was not significantly different between the combination and89 Sr Cl2groups（33.3%, 10/30）（P0.05）. Conclusion： The treatment of89 Sr Cl2combined with99Tc-MDP can increase the analgesic effect and significantly improve the curative effect without overt side effects in patients with breast cancer and bone metastasis.

关 键 词：锶放射性同位素 锝-99-亚甲基二膦酸盐 乳腺癌 骨转移 治疗 

分 类 号：R737.9[医药卫生—肿瘤]